Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel D A Tyndall

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|May 4, 2022
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2Joel D A Tyndall
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 23, 2006
GPCR agonists and antagonists in the clinicJoel D A Tyndall, Radhika Sandilya
Plos One|November 19, 2011
Honey bee dopamine and octopamine receptors linked to intracellular calcium signaling have a close phylogenetic and pharmacological relationshipKyle T Beggs, Joel D A Tyndall, Alison R Mercer
RSC Medicinal Chemistry|June 13, 2022
Covalent cannabinoid receptor ligands - structural insight and selectivity challengesIan Liddle, Michelle Glass, Joel D A Tyndall, et al.
Recent Patents on Anti-Cancer Drug Discovery|February 22, 2008
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancerJoel D A Tyndall, Michael J Kelso, Phillip Clingan, et al.
Journal of Molecular Recognition : JMR|July 1, 2004
Determination of alpha-conotoxin binding modes on neuronal nicotinic acetylcholine receptorsSébastien Dutertre, Annette Nicke, Joel D A Tyndall, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2011
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)Hayden Matthews, Marie Ranson, Joel D A Tyndall, et al.
Journal of Fungi (Basel, Switzerland)|January 20, 2022
Characterisation of <i>Candida parapsilosis</i> CYP51 as a Drug Target Using <i>Saccharomyces cerevisiae</i> as HostYasmeen N Ruma, Mikhail V Keniya, Joel D A Tyndall, et al.
Pharmaceutics|February 26, 2022
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against <i>Helicobacter pylori</i>: A Novel Approach Using Microfluidics-Engineered PLGA NanoparticlesJimin Hwang, Sonya Mros, Allan B Gamble, et al.
Pharmacological Reviews|June 29, 2017
Chemical Tools for Studying Lipid-Binding Class A G Protein-Coupled ReceptorsAnna Cooper, Sameek Singh, Sarah Hook, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|May 4, 2022
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2Joel D A Tyndall
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 23, 2006
GPCR agonists and antagonists in the clinicJoel D A Tyndall, Radhika Sandilya
Plos One|November 19, 2011
Honey bee dopamine and octopamine receptors linked to intracellular calcium signaling have a close phylogenetic and pharmacological relationshipKyle T Beggs, Joel D A Tyndall, Alison R Mercer
RSC Medicinal Chemistry|June 13, 2022
Covalent cannabinoid receptor ligands - structural insight and selectivity challengesIan Liddle, Michelle Glass, Joel D A Tyndall, et al.
Recent Patents on Anti-Cancer Drug Discovery|February 22, 2008
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancerJoel D A Tyndall, Michael J Kelso, Phillip Clingan, et al.
Journal of Molecular Recognition : JMR|July 1, 2004
Determination of alpha-conotoxin binding modes on neuronal nicotinic acetylcholine receptorsSébastien Dutertre, Annette Nicke, Joel D A Tyndall, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2011
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)Hayden Matthews, Marie Ranson, Joel D A Tyndall, et al.
Journal of Fungi (Basel, Switzerland)|January 20, 2022
Characterisation of <i>Candida parapsilosis</i> CYP51 as a Drug Target Using <i>Saccharomyces cerevisiae</i> as HostYasmeen N Ruma, Mikhail V Keniya, Joel D A Tyndall, et al.
Pharmaceutics|February 26, 2022
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against <i>Helicobacter pylori</i>: A Novel Approach Using Microfluidics-Engineered PLGA NanoparticlesJimin Hwang, Sonya Mros, Allan B Gamble, et al.
Pharmacological Reviews|June 29, 2017
Chemical Tools for Studying Lipid-Binding Class A G Protein-Coupled ReceptorsAnna Cooper, Sameek Singh, Sarah Hook, et al.
Pageof 10